Treatments for Anxiety: Meditation and Escitalopram

PHASE4CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

October 31, 2021

Study Completion Date

January 5, 2022

Conditions
Anxiety DisordersGeneralized Anxiety DisorderPanic DisorderSocial Anxiety DisorderAgoraphobia
Interventions
OTHER

Mindfulness-Based Stress Reduction

Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.

DRUG

Escitalopram

Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.

Trial Locations (3)

10016

New York University, New York

20007

Georgetown University Medical Center, Washington D.C.

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Georgetown University

OTHER

NCT03522844 - Treatments for Anxiety: Meditation and Escitalopram | Biotech Hunter | Biotech Hunter